Presepsin levels and COVID-19 severity: a systematic review and meta-analysis.
COVID-19
Disease severity
Presepsin
SARS-CoV-2
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
21
08
2022
accepted:
27
10
2022
medline:
23
10
2023
pubmed:
16
11
2022
entrez:
15
11
2022
Statut:
ppublish
Résumé
Plasmatic presepsin (PSP) is a novel biomarker reported to be useful for sepsis diagnosis and prognosis. During the pandemic, only few studies highlighted a possible correlation between PSP and COVID-19 severity, but results remain inconsistent. The present study aims to establish the correlation between PSP and COVID-19 severity. English-language papers assessing a correlation between COVID-19 and PSP from MEDLINE, PubMed, Google Scholar, Cochrane Library, MeSH, LitCovid NLM, EMBASE, CINAHL Plus and the World Health Organization (WHO) website, published from January 2020 were considered with no publication date limitations. Two independent reviewers performed data abstraction and quality assessment, and one reviewer resolved inconsistencies. The protocol was registered on PROSPERO (CRD42022325971).Fifteen articles met our eligibility criteria. The aggregate study population included 1373 COVID-19 patients who had undergone a PSP assessment. The random-effect meta-analysis was performed in 7 out of 15 selected studies, considering only those reporting the mean PSP levels in low- and high-severity cases (n = 707).The results showed that the pooled mean difference of PSP levels between high- and low-severity COVID-19 patients was 441.70 pg/ml (95%CI: 150.40-732.99 pg/ml).Our data show that presepsin is a promising biomarker that can express COVID-19 severity.
Identifiants
pubmed: 36380007
doi: 10.1007/s10238-022-00936-8
pii: 10.1007/s10238-022-00936-8
pmc: PMC9666937
doi:
Substances chimiques
Biomarkers
0
presepsin protein, human
0
Peptide Fragments
0
Lipopolysaccharide Receptors
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
993-1002Informations de copyright
© 2022. The Author(s).
Références
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497–506.
doi: 10.1016/S0140-6736(20)30183-5
pubmed: 31986264
World Health Organisation. https://covid19.who.int/ (accessed 09 June 2022).
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–81.
doi: 10.1016/S2213-2600(20)30079-5
pubmed: 32105632
pmcid: 7102538
Vahidy FS, Drews AL, Masud FN, Schwartz RL, Askary BB, Boom ML, Phillips RA. Characteristics and outcomes of COVID-19 patients during initial peak and resurgence in the Houston metropolitan area. JAMA. 2020;324:998–1000.
doi: 10.1001/jama.2020.15301
pubmed: 32789492
pmcid: 7426882
Rotondo JC, Martini F, Maritati M, Mazziotta C, Di Mauro G, Lanzillotti C, Barp N, Gallerani A, Tognon M, Contini C. SARS-CoV2 infection: new molecula, phylogenetic and pathogenetic insight efficacy of current vaccines and the potential risk of variants. Viruses. 2021;13:1687.
doi: 10.3390/v13091687
pubmed: 34578269
pmcid: 8473168
Contini C, Di Nuzzo M, Barp N, Bonazza A, De Giorgio R, Tognon M, Rubino S. The novel zoonotic COVID-19 pandemic: an expected global health concern. J Infect Dev Ctries. 2020;14:254–64.
doi: 10.3855/jidc.12671
pubmed: 32235085
Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection. 2021;49:15–28.
doi: 10.1007/s15010-020-01509-1
pubmed: 32860214
Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC, Arabi YM, Loeb M, Ng Gong M, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Machado F, Wunsch H, Crowther M, Cecconi M, Koh Y, Burry L, Chertow DS, Szczeklik W, Belley-Cote E, Greco M, Bala M, Zarychanski R, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Nainan Myatra S, Arrington A, Kleinpell R, Citerio G, Lewis K, Bridges E, Memish ZA, Hammond N, Hayden FG, Alshahrani M, Al Duhailib Z, Martin GS, Kaplan LJ, Coopersmith CM, Antonelli M, Rhodes A. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med. 2021;49:e219–34.
doi: 10.1097/CCM.0000000000004899
pubmed: 33555780
Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17:764–9.
doi: 10.1007/s10156-011-0254-x
pubmed: 21560033
Velissaris D, Zareifopoulos N, Karamouzos V, Karanikolas E, Pierrakos C, Koniari I, Karanikolas M. Presepsin as a diagnostic and prognostic biomarker in sepsis. Cureus. 2021;13: e15019.
pubmed: 34150378
pmcid: 8202808
Wu J, Hu L, Zhang G, Wu F, He T. Accuracy of presepsin in sepsis diagnosis: a systematic review and meta-analysis. PLoS ONE. 2015;10: e0133057.
doi: 10.1371/journal.pone.0133057
pubmed: 26192602
pmcid: 4507991
Zhang J, Hu ZD, Song J, Shao J. Diagnostic value of presepsin for sepsis: a systematic review and meta-analysis. Medicine. 2015;94: e2158.
doi: 10.1097/MD.0000000000002158
pubmed: 26632748
pmcid: 5059017
Zhang X, Liu D, Liu YN, Wang R, Xie LX. The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis. Crit Care. 2015;19:323.
doi: 10.1186/s13054-015-1032-4
pubmed: 26357898
pmcid: 4566362
Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, Nishida T, Irie Y, Miura M, Iguchi H, Fukui Y, Tanaka K, Nojima T, Okamura Y. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012;18:891–7.
doi: 10.1007/s10156-012-0435-2
pubmed: 22692596
Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, Fumagalli R, Mauri T, Isgrò S, Fanizza C, Romero M, Tognoni G, Latini R, Gattinoni L2014; ALBIOS Study Investigators. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care 18:R6.
Olwal CO, Nganyewo NN, Tapela K, Djomkam Zune AL, Owoicho O, Bediako Y, Duodu S. Parallels in sepsis and COVID-19 conditions: implications for managing severe COVID-19. Front Immunol. 2021;3(12): 602848.
doi: 10.3389/fimmu.2021.602848
Fukada A, Kitagawa Y, Matsuoka M, Sakai J, Imai K, Tarumoto N, Orihara Y, Kawamura R, Takeuchi S, Maesaki S, Maeda T. Presepsin as a predictive biomarker of severity in COVID-19: A case series. J Med Virol. 2021;93:99–101.
doi: 10.1002/jmv.26164
pubmed: 32530491
Zaninotto M, Mion MM, Cosma C, Rinaldi D, Plebani M. Presepsin in risk stratification of SARS-CoV-2 patients. Clin Chim Acta. 2020;507:161–3.
doi: 10.1016/j.cca.2020.04.020
pubmed: 32333860
pmcid: 7175898
Dell’Aquila P, Raimondo P, Orso D, De Luca P, Pozzessere P, Parisi CV, Bove T, Vetrugno L, Grasso S, Procacci V. A simple prognostic score based on troponin and presepsin for COVID-19 patients admitted to the emergency department: a single-center pilot study. Acta Biomed. 2021;92: e2021233.
pubmed: 34487072
pmcid: 8477102
Ducastel M, Chenevier-Gobeaux C, Ballaa Y, Meritet JF, Brack M, Chapuis N, Pene F, Carlier N, Szwebel TA, Roche N, Terrier B, Borderie D. Oxidative stress and inflammatory biomarkers for the prediction of severity and ICU admission in unselected patients hospitalized with COVID-19. Int J Mol Sci. 2021;22:7462.
doi: 10.3390/ijms22147462
pubmed: 34299080
pmcid: 8306526
Keskinidou C, Vassiliou AG, Zacharis A, Jahaj E, Gallos P, Dimopoulou I, Orfanos SE, Kotanidou A. Endothelial, immunothrombotic, and Inflammatory biomarkers in the risk of mortality in critically Ill COVID-19 patients: the role of Dexamethasone. Diagnostics (Basel). 2021;11:1249.
doi: 10.3390/diagnostics11071249
pubmed: 34359331
Schirinzi A, Cazzolla AP, Lovero R, Lo Muzio L, Testa NF, Ciavarella D, Palmieri G, Pozzessere P, Procacci V, Di Serio F, Santacroce L. New insights in laboratory testing for COVID-19 patients: looking for the role and predictive value of human epididymis secretory protein 4 (HE4) and the innate immunity of the oral cavity and respiratory tract. Microorganisms. 2020;8:1718.
doi: 10.3390/microorganisms8111718
pubmed: 33147871
pmcid: 7692217
Kocyigit A, Sogut O, Durmus E, Kanimdan E, Guler EM, Kaplan O, Yasar O. Circulating furin, IL-6, and presepsin levels and disease severity in SARS-CoV-2–infected patients. Sci Prog. 2021;104(2-suppl):00368504211026119.
Lippi G, Sanchis-Gomar F, Henry BM. Presepsin value predicts the risk of developing severe/critical COVID-19 illness: results of a pooled analysis. Clin Chem Lab Med. 2021;60:e1–3.
doi: 10.1515/cclm-2021-0848
pubmed: 34472764
Domi H, Matsuura H, Kuroda M, Yoshida M, Yamamura H. Simple prognostic factors and change of inflammatory markers in patients with severe coronavirus disease 2019: a single-center observational study. Acute Med Surg. 2021;8: e683.
doi: 10.1002/ams2.683
pubmed: 34277014
pmcid: 8275370
Dewi R, Kaswandani N, Karyanti MR, Setyanto DB, Pudjiadi AH, Hendarto A, Djer MM, Prayitno A, Yuniar I, Indawati W, Prawira Y, Handryastuti S, Sjakti HA, Hidayati EL, Muktiarti D, Soebadi A, Puspaningtyas NW, Muhaimin R, Rahmadhany A, Octavius GS, Puspitasari HA, Jasin MR, Tartila T, Putri ND. Mortality in children with positive SARS-CoV-2 polymerase chain reaction test: Lessons learned from a tertiary referral hospital in Indonesia. Int J Infect Dis. 2021;107:78–85.
doi: 10.1016/j.ijid.2021.04.019
pubmed: 33857609
pmcid: 8056472
Mirza FH, Baig FA, Syed S. Diagnostic value of novel presepsin and inflammatory biomarkers in predicting the clinical course of COVID-19. Med Bulletin of Haseki/Haseki Tip Bulteni. 2021;59:5.
Farag SM, Nasr RA, El Sheikh NG, Khattab MA. Presepsin as a predictive indicator of severity in Coronavirus disease-2019 (COVID-19). Novel Research in Microbiology Journal. 2021;5:1325–37.
doi: 10.21608/nrmj.2021.190249
Kim SW. Presepsin and monocyte distribution width as a useful early biomarker of severity in patients with covid-19. Chest. 2021;160:A1074.
doi: 10.1016/j.chest.2021.07.994
Çaglar FN, Yildiz C, Korkusuz R, Yasar KK, Isiksacan N. Serum presepsin levels among patients with COVID-19. Indian J Med Spec. 2022;13:17–22.
doi: 10.4103/injms.injms_77_21
Morales-Cely L, Bravo-Castelo LA, Bustos-Moya IG, Fuentes Y, Lozada-Arciniegas J, Ibañez-Prada ED, Narváez – Ramírez O, Ramirez P, Parra-Tanoux D, Gomez-Duque D, Gamboa-Silva E, Caceres E, Reyes LF,. 319 Presepsin as a prognostic biomarker for mortality in COVID-19 patients vs community-adquired pneumonia CAP patients in open forum infectious diseases. Oxford Univ Press. 2021;8:S265–S265.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology MOOSE group meta- analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283:2008–12.
doi: 10.1001/jama.283.15.2008
pubmed: 10789670
Rotondo JC, Martini F, Maritati M, Caselli E, Gallenga CE, Tramarin ML, Guarino M, De Giorgio R, Mazziotta C, Badiale G, Mauro Tognon M, Contini C. Advanced molecular and immunological diagnostic methods to detect SARS-CoV-2 infection. Microorganisms. 2022;10:1193. https://doi.org/10.3390/microorganisms10061193 .
doi: 10.3390/microorganisms10061193
pubmed: 35744711
pmcid: 9231257
National Institutes of Health (2014). Quality assessment tool for observational cohort and cross-sectional studies.
R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
Lisco G, De Tullio A, Stragapede A, Solimando AG, Albanese F, Capobianco M, Giagulli VA, Guastamacchia E, De Pergola G, Vacca A, Racanelli V, Triggiani V. COVID-19 and the endocrine system: a comprehensive review on the theme. J Clin Med. 2021;10:2920.
doi: 10.3390/jcm10132920
pubmed: 34209964
pmcid: 8269331
Bivona G, Agnello L, Ciaccio M. Biomarkers for prognosis and treatment response in COVID-19 patients. Ann Lab Med. 2021;41:540–8.
doi: 10.3343/alm.2021.41.6.540
pubmed: 34108281
pmcid: 8203437
Ahmed S, Mansoor M, Shaikh MS, Siddiqui I. Presepsin as a predictive biomarker of severity in COVID-19: a systematic review. Indian J Crit Care Med. 2021;25:1051–4.
doi: 10.5005/jp-journals-10071-23967
pubmed: 34963726
pmcid: 8664043
Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N, Belgian,. Collaborative group on COVID-19 hospital surveillance time between symptom onset hospitalisation and recovery or Death: statistical analysis of Belgian COVID-19 patients. Int J Environ Res Public Health. 2020;17:7560.
doi: 10.3390/ijerph17207560
pubmed: 33080869
pmcid: 7589278